Are you wondering why some people have increased the risk of diabetes and obesity? Despite eating more and intaking more calories, some people have a reduced threat of developing heart diseases, diabetes, and being overweight. Many experts believe that this difference exists because of the genetic mutations.

In this article, we have mentioned the reason why some people have less risk of diabetes and obesity. Have a look!

According to a study conducted at Brigham and Women’s Hospital, it was found that mutation in the DNA of some people lowers the risk of diabetes and obesity. The gene mutation of SGLT1 found in some people is responsible for reducing the high levels of sugar in the gut. This variant of the gene is capable of lowering the risk of diabetes, heart failure, obesity, and death.

The experts were able to find a link to the increased level of sugar and genetic mutation in SGLT1. The increase in blood sugar is because of the dietary glucose.

Moreover, carbohydrates are broken down into pieces in the small intestine. This produces component like glucose; it is absorbed into the tissues. The transporter of the glucose is SGLT1. The researchers believed that SGLT1 might be capable of lowering the glucose uptake in the small intestine. This will decrease a load of carbohydrates after a meal.

There are some mutations of SGLT1 that will result in dysfunction of protein. This may lead to malabsorption of nutrients or can even lead to death in infants. On the other hand, some mutations might slightly change the function of the protein.

For studying the impact of SGLT1 genetic mutations, a validation analysis was conducted in the European-Finnish population. In the African-American population, replication analysis was conducted. In addition, the experts performed Mendelian randomization. It was performed to evaluate the long-term impacts of reduced blood sugar levels through these mutations on cardiovascular and metabolic disease.

The researchers reported that 7.5% of African-Americana and 16% of European-American participants had the SGLT1 mutation. In this study, it was found that people with this SGLT1 mutation were safe from the increase in blood glucose levels. Through the Mendelian randomization analysis, it was stated that these people were at reduced of experiencing heart disease, obesity, and diabetes in the future.

In the end, SGLT1 receptors will be beneficial for treating cardiometabolic disease. For developing drugs with SGLT1 inhibit, it might take many years. It will even require clinical trials.